Rasburicase biosimilar (Jilin Xiuzheng Pharmaceutical/Hangzhou Biodoor Biotechnology)

拉布立酶生物类似药 (Jilin Xiuzheng Pharmaceutical/Hangzhou Biodoor Biotechnology)

Report date: 2026/05/22 20:01:29

Base Information

Drug NameRasburicase biosimilar (Jilin Xiuzheng Pharmaceutical/Hangzhou Biodoor Biotechnology)

Drug Alias Name拉布立酶生物仿制药（Jilin Xiuzheng Pharmaceutical New Medicine Development）Recombinant urate oxidase(Biodoor)重组尿酸氧化酶（杭州北斗）

ClassificationBiologics > BiosimilarBiologics > Protein drugs > Enzyme > Recombinant enzymeBiologics > Protein drugs > Recombinant protein > Recombinant enzyme

Mechanisms of ActionUrate oxidases replacements

TargetsUrate oxidase

Therapy Area/IndicationsSolid tumoursHyperuricemiaLymphoma +[4]

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryMainland China

CombinationsNo

Global Highest StatusPhase 2 Clinical

Highest Status in ChinaPhase 2 Clinical

Originator CompaniesBiodoor Biotechnology Co Ltd

China Registration ClassN/A

Develop Information

Active CompaniesBiodoor Biotechnology Co Ltd

Inactive CompaniesN/A

Active IndicationsSolid tumoursLymphomaLeukemia

Inactive IndicationsHyperuricemia

Other Information

ATC CodeV03AF07